熊去氧胆酸胶囊对黄疸型肝炎退黄的疗效观察(2)
[5] Heathcote EJ, Cauch-Dudek K, Walker V, et al. The Canadian Multicenter Double-blind Randomized Controlled Trial of ursodeoxycholic acid in primary billiary cirrhosis. Hepatology， 1994，19：1149-1156.
[6] Lindor KD. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid study Group. N Engl J Med， 1997，336：691-695.
[7] Medina JF, Martinez A, Vazquez JJ, et al. Decreased antion excganger immunoreactivity in the liver of patients with primary billarycirrhosis. Hepatology，1997，25：12-17.
, 百拇医药
[8] Fickert P, Zollner G, Fuchsbichler A, et al. Effects of ursodeoxycholic and cholic acid feeding on hepatocellular transporter expression in mouse liver. Gastroenterology，2001，121：170-183.
[9] Beuers U, Blizer M, Chittattu A, et al. Taurourodeoxycholic acid inserts the apical conjugate export pump, Mrp2, into canalicular membranes and stimulates organic antion secretion by protein kinase C-dependent mechanisms in cholestatic rat liver. Hepatology， 2001，33：1206-1216.
, 百拇医药
[10]Kurz AK,Graf D,Schmitt M,et al. Tauroursodeoxycholate-induced choleresis involves p38(MAPK)activation andtranslocation of the bile salt expoetpump in rats.Gastroenterology，2001，121:407-19.
[11]Berge Henegouwen,Adiler G, et al. Prevention of gallstone-related complications with ursodeoxycholic acid.Gallstones: Pathogenesis and Treatment，2004：147-156.
[12]Colecchia A.Effect of chronic administration of ursodeoxycholic acid on gastrointestinal motility in gallstones and healthy controls.J Hepatol，2004， 90：291.
, http://www.100md.com
[13]Sven Fischer,lris Muler,et al.Ursodeoxycholic acid decreases viscosity and sedimentable fractions ofgallbladder bile in patients with cholesterol gallstones.Eur J G astroenterol Hepatol，2004，16:305-311.
[14]Hirano F. Effects of ursodeoxycholic acid anb chenodeoxycholic acid on major histocompatibility complex class l gene expression.J Gastroenterol，1996，31:55-60.
[15]Nishigaki Y,Ohnishi H, et al.Ursodeoxycholic acid corrects defective natural killer activity by inhibitingprostaglandin E2 production in primary billiary cirrhosis.Dig Dis Sci，1996，41(7):1487-1493.[16]Kano M, Shoda J,et al Effects of long -term ursodeoxycholate administration on expression levels ofsecretory low-molecular -weight phospholipases 2 and mucin genes in gallbladders anb biliarycomposition in patients with multiple cholesterol stones.Hepatology,1998，28:302-313.
, 百拇医药
[17]Kullmann F，Arndt H,et al.beneficial effect of ursodeoxycholic acid on mucosal damage in trinitrobenzene sulphonic E, ur J Gastroenterol Hepatol，1997，9:1205-1211.
[18]Quist RG,Ton-Nu HT,et al.Activation of mast cells by bill acids.Gastroenterology，1991，101:446-456.
[19]Saitoh O,Nakagawa K,et al. Bile acaids inhibits tumour necrosis factor α-induced interleukin-8 production in human colon epithelia cells.J Gastroenterol Hepatol，1998，13:1212-1217.
[20]Yamazaki K，Ohtsubo N,et al.Ursodeoxycholic acid inhibits histamine release from rat peritoneal mast cells.Int Hepatol Commun，1995，4:207-215.
[21]Lazaridis KN,Gores GJ,et al.Ursodeoxycholic acid'medchanisms of action and clinical use in hepatobiliary disorders.J Hepatol.2001，35:134-146., http://www.100md.com(阿色叶木•麦米提敏)
[6] Lindor KD. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid study Group. N Engl J Med， 1997，336：691-695.
[7] Medina JF, Martinez A, Vazquez JJ, et al. Decreased antion excganger immunoreactivity in the liver of patients with primary billarycirrhosis. Hepatology，1997，25：12-17.
, 百拇医药
[8] Fickert P, Zollner G, Fuchsbichler A, et al. Effects of ursodeoxycholic and cholic acid feeding on hepatocellular transporter expression in mouse liver. Gastroenterology，2001，121：170-183.
[9] Beuers U, Blizer M, Chittattu A, et al. Taurourodeoxycholic acid inserts the apical conjugate export pump, Mrp2, into canalicular membranes and stimulates organic antion secretion by protein kinase C-dependent mechanisms in cholestatic rat liver. Hepatology， 2001，33：1206-1216.
, 百拇医药
[10]Kurz AK,Graf D,Schmitt M,et al. Tauroursodeoxycholate-induced choleresis involves p38(MAPK)activation andtranslocation of the bile salt expoetpump in rats.Gastroenterology，2001，121:407-19.
[11]Berge Henegouwen,Adiler G, et al. Prevention of gallstone-related complications with ursodeoxycholic acid.Gallstones: Pathogenesis and Treatment，2004：147-156.
[12]Colecchia A.Effect of chronic administration of ursodeoxycholic acid on gastrointestinal motility in gallstones and healthy controls.J Hepatol，2004， 90：291.
, http://www.100md.com
[13]Sven Fischer,lris Muler,et al.Ursodeoxycholic acid decreases viscosity and sedimentable fractions ofgallbladder bile in patients with cholesterol gallstones.Eur J G astroenterol Hepatol，2004，16:305-311.
[14]Hirano F. Effects of ursodeoxycholic acid anb chenodeoxycholic acid on major histocompatibility complex class l gene expression.J Gastroenterol，1996，31:55-60.
[15]Nishigaki Y,Ohnishi H, et al.Ursodeoxycholic acid corrects defective natural killer activity by inhibitingprostaglandin E2 production in primary billiary cirrhosis.Dig Dis Sci，1996，41(7):1487-1493.[16]Kano M, Shoda J,et al Effects of long -term ursodeoxycholate administration on expression levels ofsecretory low-molecular -weight phospholipases 2 and mucin genes in gallbladders anb biliarycomposition in patients with multiple cholesterol stones.Hepatology,1998，28:302-313.
, 百拇医药
[17]Kullmann F，Arndt H,et al.beneficial effect of ursodeoxycholic acid on mucosal damage in trinitrobenzene sulphonic E, ur J Gastroenterol Hepatol，1997，9:1205-1211.
[18]Quist RG,Ton-Nu HT,et al.Activation of mast cells by bill acids.Gastroenterology，1991，101:446-456.
[19]Saitoh O,Nakagawa K,et al. Bile acaids inhibits tumour necrosis factor α-induced interleukin-8 production in human colon epithelia cells.J Gastroenterol Hepatol，1998，13:1212-1217.
[20]Yamazaki K，Ohtsubo N,et al.Ursodeoxycholic acid inhibits histamine release from rat peritoneal mast cells.Int Hepatol Commun，1995，4:207-215.
[21]Lazaridis KN,Gores GJ,et al.Ursodeoxycholic acid'medchanisms of action and clinical use in hepatobiliary disorders.J Hepatol.2001，35:134-146., http://www.100md.com(阿色叶木•麦米提敏)